Industrial Data Labs announced the close of its $1.5 million seed round of funding. Photo via Getty Images

A Houston startup that's on a mission to transform and expedite data processing for its industrial clients has raised seed funding.

Industrial Data Labs announced this week that it's closed a $1.5 million seed round of funding. The company has created an applied artificial intelligence technology for the pipe, valve, fitting, and flange, or PVF, industry's inside sales team. The terms of the seed round were not disclosed.

"Our groundbreaking AI-Powered Inside Sales Copilot is transforming the way inside sales teams operate in the PVF industry," Marty Dytrych, co-founder and CEO of Industrial Data Labs, says in a news release. "By embedding our solution into existing BOM and MRO workflows, we empower teams to achieve unmatched efficiency, accuracy, and sales performance.”

Dytrych founded the company with COO Aaron deOliveira and CTO Tige Richardson in 2020. Per the release, Industrial Data Labs will use the funding to continue growing to continue delivering its "solutions that enhance efficiency and create new opportunities" within the PVF industry.

The company did not disclose its seed investors, but reported that Marshal Kushniruk is among the investors and is a member of the company's board of directors.

"Industrial Data Labs' innovative application of AI technology has the potential to bring significant transformation to the industrial sales landscape," Kushniruk says in the release. We are thrilled to support their mission and drive impactful change within the PVF industry.”

Mark Janzen is an early investor in Industrial Data Labs.

"Industrial Data Labs is at the forefront of Applied AI solutions in the industrial sector," he adds. "We believe their commitment to delivering unparalleled value to clients through their Inside Sales Copilot will have a lasting impact on the industry.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”